|
1
|
Wu HM, Zhao ZK, Li XX, Wang SL, Ai KX. Nano-drug codelivery system of vincristine and gemcitabine loaded hyaluronan-altered hollow mesoporous silica nanoparticles: investigation of in vitro drug release and anticancer activity in pancreatic cancer cells. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2025:10.1007/s00210-025-04116-9. [PMID: 40266301 DOI: 10.1007/s00210-025-04116-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2025] [Accepted: 03/27/2025] [Indexed: 04/24/2025]
Abstract
This study involves the co-loading of Vincristine (VC) and Gemcitabine (GT), two anticancer compounds, into hollow mesoporous silica nanoparticles (HA-SS-HMS) to specifically target pancreatic cancer cells, utilizing targeting and capping agent of hyaluronic acid (HA) and redox-sensitive linkers of S-S bonds. Well-dispersed HA-SS-HMS are fabricated with a diameter of less than 150 nm. Comprehensive chemical-physical characterization of the fabricated HA-SS-HMS utilized FTIR, FE-SEM, TEM, DLS, TGA, and BET techniques. The drug release experiment demonstrated regulated and pH-responsive behavior in the presence of HAase and GSH at pH levels 5.0 and 7.4. The targeting capability and dispersion of VC/GT@HA-SS-HMS in CD44(+) PANC- 1 pancreatic cancer cells were evidenced by fluorescence microscopic imaging. Furthermore, VC/GT@HA-SS-HMS demonstrated superior synergistic cytotoxicity and apoptotic rates relative to VC or GT-loaded HA-SS-HMS and the free VC/GT combination against the PANC- 1 cell line. The biochemical staining outcomes indicated a significant change in apoptosis ratio in cells treated with VC/GT@HA-SS-HMS. Collectively, our research demonstrates the promise of HA-SS-HMS as an effective nanoparticle-based approach for targeted and induced codelivery of VC/GT combination in the treatment of pancreatic cancer cells.
Collapse
Affiliation(s)
- Hui-Min Wu
- Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, No. 507, Zhengmin Road, Yangpu District, Shanghai, 200092, China
| | - Ze-Kun Zhao
- Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, No. 507, Zhengmin Road, Yangpu District, Shanghai, 200092, China
| | - Xin-Xing Li
- Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, No. 507, Zhengmin Road, Yangpu District, Shanghai, 200092, China
| | - Sheng-Lan Wang
- Department of Gastroenterology, Institute of Digestive Diseases, Tongji Hospital, Tong Ji University, School of Medicine, Tongji University, Shanghai, 200092, China
| | - Kai-Xing Ai
- Department of General Surgery, Tongji Hospital, School of Medicine, Tongji University, No. 507, Zhengmin Road, Yangpu District, Shanghai, 200092, China.
| |
Collapse
|
|
2
|
Zhang X, Zhang H, Liu X, Wang J, Li S, Gao P. Review and Future Perspectives of Stimuli-Responsive Bridged Polysilsesquioxanes in Controlled Release Applications. Polymers (Basel) 2024; 16:3163. [PMID: 39599255 PMCID: PMC11598018 DOI: 10.3390/polym16223163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Revised: 10/31/2024] [Accepted: 11/11/2024] [Indexed: 11/29/2024] Open
Abstract
Bridged polysilsesquioxanes (BPSs) are emerging biomaterials composed of synergistic inorganic and organic components. These materials have been investigated as ideal carriers for therapeutic and diagnostic systems for their favorable properties, including excellent biocompatibility, physiological inertia, tunable size and morphology, and their extensive design flexibility of functional organic groups to satisfy diverse application requirements. Stimuli-responsive BPSs can be activated by both endogenous and exogenous stimuli, offering a precise, safe, and effective platform for the controlled release of various targeted therapeutics. This review aims to provide a comprehensive overview of stimuli-responsive BPSs, focusing on their synthetic strategies, biocompatibility, and biodegradability, while critically assessing their capabilities for controlled release in response to specific stimuli. Furthermore, practical suggestions and future perspectives for the design and development of BPSs are presented. This review highlights the significant role of stimuli-responsive BPSs in advancing biomedical research.
Collapse
Affiliation(s)
- Xin Zhang
- Shandong Key Laboratory of Digital Traditional Chinese Medicine, Institute of Pharmaceutical Research, Shandong University of Traditional Chinese Medicine, Jinan 250355, China;
| | - Han Zhang
- Department of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; (H.Z.); (J.W.); (S.L.)
| | - Xiaonan Liu
- Shandong Key Laboratory of Digital Traditional Chinese Medicine, Institute of Pharmaceutical Research, Shandong University of Traditional Chinese Medicine, Jinan 250355, China;
| | - Jiao Wang
- Department of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; (H.Z.); (J.W.); (S.L.)
| | - Shifeng Li
- Department of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China; (H.Z.); (J.W.); (S.L.)
| | - Peng Gao
- Shandong Key Laboratory of Digital Traditional Chinese Medicine, Institute of Pharmaceutical Research, Shandong University of Traditional Chinese Medicine, Jinan 250355, China;
| |
Collapse
|
|
3
|
Yang S, Sun B, Liu F, Li N, Wang M, Wu P, Wu GL, Fang H, He Y, Zhou W, Xiao H, Tan X, Tang L, Zhu S, Yang Q. NIR-II Imaging-Guided Mitochondrial-Targeting Organic Nanoparticles for Multimodal Synergistic Tumor Therapy. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2023:e2207995. [PMID: 36942859 DOI: 10.1002/smll.202207995] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 02/17/2023] [Indexed: 06/18/2023]
Abstract
Effectively interfering energy metabolism in tumor cells and simultaneously activating the in vivo immune system to perform immune attacks are meaningful for tumor treatment. However, precisely targeted therapy is still a huge challenge. Herein, a mitochondrial-targeting phototheranostic system, FE-T nanoparticles (FE-T NPs) are developed to damage mitochondria in tumor cells and change the tumor immunosuppressive microenvironment. FE-T NPs are engineered by encapsulating the near-infrared (NIR) absorbed photosensitizer IR-FE-TPP within amphiphilic copolymer DSPE-SS-PEG-COOH for high-performing with simultaneous mitochondrial-targeting, near-infrared II (NIR-II) fluorescence imaging, and synchronous photothermal therapy (PTT) /photodynamic therapy (PDT) /immune therapy (IMT). In tumor treatment, the disulfide in the copolymer can be cleaved by excess intracellular glutathione (GSH) to release IR-FE-TPP and accumulate in mitochondria. After 808 nm irradiation, the mitochondrial localization of FE-T NPs generated reactive oxygen species (ROS), and hyperthermia, leading to mitochondrial dysfunction, photoinductive apoptosis, and immunogenic cell death (ICD). Notably, in situ enhanced PDT/PTT in vivo via mitochondrial-targeting with FE-T NPs boosts highly efficient ICD toward excellent antitumor immune response. FE-T NPs provide an effective mitochondrial-targeting phototheranostic nanoplatform for imaging-guided tumor therapy.
Collapse
Affiliation(s)
- Sha Yang
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
- Tumor Pathology Research Group & Department of Pathology, Institute of Basic Disease Sciences & School of Basic Medical Sciences, Xiangnan University, Chenzhou, Hunan, 423000, China
| | - Bin Sun
- State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, China
| | - Fen Liu
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Na Li
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Minghui Wang
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Peixian Wu
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Gui-Long Wu
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Huilong Fang
- Tumor Pathology Research Group & Department of Pathology, Institute of Basic Disease Sciences & School of Basic Medical Sciences, Xiangnan University, Chenzhou, Hunan, 423000, China
| | - Yuxuan He
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Wei Zhou
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Hao Xiao
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Xiaofeng Tan
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| | - Li Tang
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
- Key Laboratory of Tropical Medicinal Plant Chemistry of Ministry of Education, College of Chemistry and Chemical Engineering, Hainan Normal University, Haikou, Hainan, 571158, China
| | - Shoujun Zhu
- State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun, 130012, China
| | - Qinglai Yang
- Center for Molecular Imaging Probe, Hunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China
| |
Collapse
|